A Step Towards Personalized Medicine: PET-PSMA Imaging in Prostate Cancer VL

PRINCE Trial Highlights Early Detection of Prostate Cancer Progression with PSMA PET-CT - Michael Hofman

Details
Michael Hofman discusses the development of new criteria for evaluating prostate cancer progression using PSMA PET-CT scans. This work aims to standardize response evaluation and potentially replace the current PCWG3 guidelines that rely on CT and bone scans. Using data from the PRINCE trial, Dr. Hofman's team demonstrates high inter-reader agreement for the new criteria, with almost perfect agree...

Phase 3 CLARIFY Trial Investigates 64Cu-SAR-bisPSMA PET for Improved Prostate Cancer Detection - Louise Emmett

Details
Louise Emmett discusses the novel copper-64 bisPSMA agent for prostate cancer imaging. She explains its unique features, including a 12-hour half-life and bifid peptide structure, which potentially offer improved imaging characteristics over existing PSMA agents. Dr. Emmett highlights early study results showing higher intensity uptake in cancer cells compared to gallium PSMA-11. The conversation...

CLARIFY Trial: Advancing Prostate Cancer Imaging with 64Cu-SAR-bisPSMA PET - Neal Shore

Details
Neal Shore discusses a new 64Cu-SAR-bisPSMA PET diagnostic agent for prostate cancer imaging with Phillip Koo. Dr. Shore highlights the unique features of this compound, including its bivalent structure and longer half-life compared to existing PSMA PET agents. He explains how these characteristics allow for next-day imaging, potentially improving detection rates and clinical flexibility. Dr. Shor...

PSMA PET in Prostate Cancer: Balancing Sensitivity and Clinical Relevance - Ravi Madan

Details
Oliver Sartor discusses with Ravi Madan the implications of using PSMA PET scans in metastatic castration-resistant prostate cancer. Dr. Madan highlights concerns about prematurely changing treatments based on PSMA PET findings without established criteria for progression. He emphasizes the distinction between radiological progression and treatment failure, noting the lack of validated parameters...

PSMA-PET/CT Guided Salvage Radiotherapy: Improving Prostate Cancer Outcomes - Constantinos Zamboglou

Details
Zach Klaassen interviews Constantinos Zamboglou about a study on PSMA-PET/CT-guided salvage radiotherapy for recurrent prostate cancer after surgery. Dr. Zamboglou presents findings from a comparative analysis of PSMA-PET-guided and non-PSMA-guided salvage radiotherapy, using data from the SAKK09/10 trial and a retrospective database. The study demonstrates improved short- and mid-term biochemical...

Patient Selection for PSMA Radioligand Therapy - Ephraim Parent

Details
Phillip Koo engages in a conversation with Ephraim Parent on the pivotal role of PSMA PET imaging in selecting patients for radioligand therapy (RLT). Dr. Parent emphasizes the critical importance of accurately identifying patients through PSMA PET imaging to ensure successful outcomes with Pluvicto therapy. He outlines the standardized practice of evaluating patients with PSMA PET to detect PSMA-...

NCCN Guidelines: A Framework for PET Imaging Integration in Prostate Cancer Care - Edward Schaeffer

Details
In this collaborative discussion, Alicia Morgans and Edward (Ted) Schaeffer examine the evolving guidelines for integrating PET imaging into the diagnosis and treatment of prostate cancer. Dr. Schaeffer emphasizes that these NCCN guidelines, which frequently adapt to new medical developments, act as a flexible framework rather than a rigid rulebook. The conversation explores the application of PSM...

OSPREY and CONDOR Trials - Evaluating F-18 DCFPyL PSMA Imaging for Prostate Cancer - Michael J. Morris

Details
A Step Towards Personalized Medicine: PSMA-PET Imaging in Prostate Cancer F-18 DCFPyL PSMA Imaging for Prostate Cancer: OSPREY and CONDOR. Independent Medical Education Initiative Supported by Progenics Pharmaceuticals, Inc. a subsidiary of Lantheus Holdings, Inc. Biographies: Michael Morris, MD, Medical Oncologist Clinical Director, Genitourinary Medical Oncology Service & Prostate Cancer Section...

The Biology of Prostate Cancer Metastasis and What PSMA Imaging Is Teaching Us: Presentation and Discussion - Kenneth J. Pienta

Details
A Step Towards Personalized Medicine: PSMA PET Imaging in Prostate Cancer. The Biology of Prostate Cancer Metastasis and What PSMA Imaging is Teaching Us Independent Medical Education Initiative Supported by Progenics Pharmaceuticals, Inc. a subsidiary of Lantheus Holdings, Inc. Biographies: Presenter: Kenneth J. Pienta, MD, is the Donald S. Coffey Professor at the Brady Urological Institute at Jo...

Diagnostic Molecular Imaging for Prostate Cancer in the United States: A Focus on Lesion Localization and Distribution Using 18F-DCFPyL PET/CT at Biochemical Recurrence Lecture & Discussion - Andrei H...

Details
A Step Towards Personalized Medicine: PSMA PET Imaging in Prostate Cancer. Diagnostic Molecular Imaging for Prostate Cancer in the United States - Andrei H Iagaru Independent Medical Education Initiative Supported by Progenics Pharmaceuticals, Inc. a subsidiary of Lantheus Holdings, Inc. Biographies: Andrei H. Iagaru, MD, FACNM, Professor of Radiology - Nuclear Medicine, Chief, Division of Nuclear...